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followed at our Pediatric Rheumatology Unit. We  identiﬁed
289 (5.1%) c-SLE patients that fulﬁlled the American Collegentroduction
hildhood-onset systemic polyarteritis nodosa (c-PAN)
s a rare necrotizing arteritis characterized by the pres-
nce of aneurismal nodules, stenosis or occlusion of
mall and medium-sized vessels of the entire body.1–3
ecently, the European League Against Rheumatism
EULAR)/Paediatric Rheumatology International Trials Orga-
isation (PRINTO)/Paediatric Rheumatology European Society
PRES) proposed new validated criteria for c-PAN diagnosis.
his new criteria studied 150 patients with c-PAN worldwide
nd demonstrated high sensitivity and speciﬁcity for the
iagnosis of this systemic vasculitis.3
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icenses/by-nc-nd/4.0/).Childhood-onset systemic lupus erythematosus (c-SLE)
is an autoimmune and multisystemic disorder.4,5 Inﬂam-
mation of the blood vessels is a common disease man-
ifestation and may affect small, medium and large-sized
vessels.4–7
Moreover, c-SLE and c-PAN may present similar clinical
manifestations and laboratory alterations. However, to our
knowledge the overlap syndrome of these two diseases has
not previously been described. Therefore, we  reviewed our
data from January 1983 to July 2013 and included 5593 patientsof Rheumatology (ACR)6 classiﬁcation criteria and 15 c-PAN
patients that fulﬁlled the EULAR/PRINTO/PRES criteria.7 We
e under the CC BY-NC-ND license (http://creativecommons.org/
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described herein a patient (0.34%) who  presented a possible
c-PAN and c-SLE overlap.
Case  report
A 9-year-old girl presented tender subcutaneous nodules
on the feet, arterial hypertension, right hemiplegia and
dysarthric speech. She was hospitalized due to stroke, numb-
ness in her extremities and left foot drop. Brain computer
tomography showed ischemic stroke. Magnetic resonance
angiography revealed stenosis in the middle cerebral and
internal carotid arteries. Electroneuromyography identiﬁed a
mononeuropathy of the left posterior tibial nerve. Therefore,
C-PAN was diagnosed according to the EULAR/PRINTO/PRES
criteria.3 Laboratory tests showed hemoglobin 12 g/dL,
white blood cell count (WBC) 5500/mm3 (75% neutrophils,
19% lymphocytes, 5% monocytes and 1% eosinophils),
platelets 264,000/mm3, erythrocyte sedimentation rate (ESR)
45 mm/1st hour, C-reactive protein (CRP) 0.9 mg/dL (normal
0–0.3), aspartate aminotransferase 22 U/L (normal 15–40), ala-
nine aminotransferase 21 U/L (normal 10–35), urea 26 mg/dL
(normal range 15–45 mg/dL) and creatinine 0.7 mg/dL (nor-
mal  range 0.6–0.9 mg/dL). Urinalysis and 24-h proteinuria
were normal. Immunological tests showed antinuclear anti-
bodies (ANA) 1:320 (ﬁne speckled pattern), and negative
anti-double-stranded DNA (anti-dsDNA), anti-Sm, anti-RNP,
antineutrophil cytoplasmic autoantibodies (ANCA), IgG and
IgM anticardiolipin antibodies, and lupus anticoagulant.
She received three intravenous methylprednisolone pulse
therapy, followed by prednisone (1.4 mg/kg/day) that was
progressively  tapered, aspirin (150 mg/day), six months of
intravenous cyclophosphamide (500 mg/m2/month) and after
that she was treated with azathioprine (1.6 mg/kg/day) for 19
months. At 13 years and 10 months, she presented multiple
erythematous scaly plaques over the malar area, ears and
chest. The skin biopsy from the left ear evidenced focal
psoriasiform hyperplasia with perivascular mononuclear
inﬁltrate and direct immunoﬂuorescence showed granular
immunoglobulin G (IgG), IgA, IgM and C3 deposits at the
dermoepidermal junction. She was treated with topical
hydrocortisone 1% with improvement of skin lesions after
3 months. At the age of 14 years and 9 months, she pre-
sented malar rash, photosensitivity, edema in lower limbs
and arterial hypertension. At that moment, hemoglobin was
11.61 g/dL, WBC  was 3500/mm3 (80% neutrophils, 15% lym-
phocytes and 5% monocytes), platelets 391,000/mm3, ESR was
54 mm/1st hour, CRP 7.0 mg/dL, urea 20 mg/dL and creatinine
0.4 mg/dL. Urinalysis showed leukocyturia and hematuria.
The proteinuria was 1.7 g/day. ANA was 1/1280 (homogeneous
nuclear pattern) and anti-dsDNA antibodies were posi-
tive. Anti-Sm, anti-RNP, ANCA, IgG and IgM anticardiolipin
antibodies and lupus anticoagulant were negative. C3 was
41 mg/dL (range 79–152) and C4 was 4.5 mg/dL (range 16–38).
Renal biopsy showed focal proliferative and membranous
glomerulonephritis with immune deposits of C1q, C3, IgG, IgM
and IgA. She fulﬁlled the American College of Rheumatology
classiﬁcation criteria for SLE8 and the SLE Disease Activity
Index 2000 (SLEDAI-2K)9 was 18. She was treated with 0 1 6;5 6(6):551–553
prednisone (0.6 mg/kg/day), hydroxychloroquine
(6.0 mg/kg/day) and mycophenolate mofetil (2.0 g/day).
Discussion
We reported herein a unique case of a possible c-PAN and c-SLE
overlap over a period of 30 years at our tertiary hospital.
It was observed that our patient had stenosis in the middle
cerebral and internal carotid arteries compatible with c-PAN 5
years before the c-SLE diagnosis, thus suggesting the presence
of two different autoimmune diseases over a long period of
time.
Primary vasculitis has been rarely reported in association
with SLE.6,7 Of note, Kawasaki disease is an acute childhood
systemic vasculitis that mainly affects the medium vessels,
particularly coronary arteries, and may overlap with c-SLE.6
Moreover, subacute cutaneous lupus erythematosus occurs
in 7–27% of adults with SLE and has been rarely reported
in pediatric lupus population. The lesions are papulosqua-
mous, affecting areas exposed to sunlight, as evidenced in
our patient.10 Interestingly, the subacute cutaneous lupus is a
new topic of the recent Systemic Lupus International Collab-
orating Clinics (SLICC) criteria, validated for adult and c-SLE
populations.11,12
Our case fulﬁlled the c-PAN diagnosis criteria. According
to the new pediatric EULAR/PRINTO/PRES criteria,3 a patient
is classiﬁed with c-PAN if presents necrotizing vasculitis
involving medium or small arteries or an angiographic abnor-
mality showing aneurysm, stenosis, or occlusion of a medium
or small-sized artery, plus one of these following criteria:
skin involvement (livedo reticularis, skin nodules or infarcts),
peripheral neuropathy, arterial hypertension, myalgia or
muscle tenderness and renal involvement. Remarkably, sensi-
tivity and speciﬁcity of these new criteria for c-PAN diagnosis
were 89.6% and 99.6%, respectively.3
Since the two diseases coexisted over a long period
time, the association between them may suggest an over-
lap syndrome. Indeed, the subsequent change of clinical
and laboratorial abnormalities with the presence of speciﬁc
autoantibodies, decreased complement levels,13 and skin and
kidney biopsies conﬁrmed the c-SLE diagnosis. Furthermore,
the presence of ANCA was reported in six out of 47 tested
c-PAN patients in a multicenter study2 and ANA is generally
negative in c-PAN.1
However, all of c-PAN manifestations of our patient may
be evidenced in c-SLE and we cannot exclude the possibility
that the ﬁrst signs and symptoms may be attributed solely
to lupus. Therefore, this patient may be suffering from c-SLE
with visceral manifestations of vascultis mimicking c-PAN.
In conclusion, we  described herein a possible overlap syn-
drome of two autoimmune diseases, where c-PAN occurred
ﬁve years before the c-SLE diagnosis.
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